Urs Kerkmann

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt et al. · The Lancet · 2022 · 211 citations

Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, Multicentre Phase 3 +6

Ultraviolet B-Induced DNA Damage in Human Epidermis Is Modified by the Antioxidants Ascorbic Acid and D-α-Tocopherol

Marianne Placzek, Sabine Gaube, Urs Kerkmann et al. · Journal of Investigative Dermatology · 2005 · 123 citations · Full text

Dna Damage, Antioxidants Ascorbic Acid, Biochemistry +8

Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from <scp>PHOENIX</scp> 1

Phoebe Rich, Marc Bourcier, Howard Sofen et al. · British Journal of Dermatology · 2013 · 110 citations · Full text

Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

Kristian Reich, Jean-Paul Ortonne, Urs Kerkmann et al. · Dermatology · 2010 · 59 citations

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study

Alice B. Gottlieb, Robert E. Kalb, Andrew Blauvelt et al. · Journal of the American Academy of Dermatology · 2011 · 54 citations

Inflammation, Medicine, Plaque Psoriasis +6